Glucagon HGH Human Growth Hormone Peptide GLP-1 7-37 Acetate For Diabetes Mellitus Treatment

Glucagon HGH Human Growth Hormone Peptide GLP-1 7-37 Acetate For Diabetes Mellitus Treatment

Description

Glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene. The major source of GLP-1 in the body is the intestinal L cell that secretes GLP-1 as a gut hormone. The biologically active forms of GLP-1 are:GLP-1-(7-37) and GLP-1-(7-36)NH2.

GLP-1 secretion by L cells is dependent on the presence of nutrients in the lumen of the small intestine. The secretagogues (agents that cause or stimulate secretion) of this hormone include major nutrients like carbohydrate, protein and lipid. Once in the circulation, GLP-1 has a half life of less than 2 minutes, due to rapid degradation by the enzyme dipeptidyl peptidase-4.

GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells. It is a potent insulinotropic hormone.

Specification

GLP-1 (7-37) Acetate

Sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly

Alias : 7-37-Glucagon-likepeptide I (human);Glucagon-relatedpeptide 1 (Rana catesbeiana),3-L-glutamicacid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-de-L-lysine-
Cas No.: 106612-94-6
Molecular Formula: C151H228N40O47
M.S.:

Molecular Weight: 3355.74
Purity (HPLC): 99.0%
Appearance: White powder
Single Impurity (HPLC): 1.0%
Amino Acid Composition: 10% of theoretical
Peptide Content (N%): 80% (by %N)
Water Content (Karl Fischer): 6.0%
Acetate Content (HPIC): 15.0%

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8℃ preservation

Usage : GLP-1 can obviously improve the blood glucose in type 2 diabetes animal models or patients through a variety of mechanisms, which promote the regeneration and repair of islet beta cells, increase the number of beta cells is particularly significant role, provides a very good prospect for the treatment of type 2 diabetes mellitus.

Application

Effect of GLP-1 GLP-1 can protect beta cells can act on the pancreatic beta cells, promote the synthesis of insulin, insulin gene transcription and secretion and can stimulate the proliferation and differentiation of islet beta cells, inhibit the apoptosis of pancreatic beta cells, increase the number of beta cell of islet [2-5]. In addition, GLP-1 also can be applied to the pancreatic alpha cells, strongly inhibit the release of glucagon, and act on the islet delta cells, promote the secretion of somatostatin, somatostatin cells and can be used as a paracrine hormone involved in the inhibition of glucagon.

GLP-1 with glucose concentration dependent hypoglycemic effect, i.e. only rise in glucose levels under the condition of GLP-1, only play a hypoglycemic effect, but in normal blood sugar levels, caused no further decrease. The glucose concentration dependence of the GLP-1 is its hypoglycemic properties of clinical application safety of foundation and security, thereby avoiding people may cause severe hypoglycemia in patients with existing drug treatment for diabetes and scheme of worry.

Physiological functions of GLP-1 include

GLP-1 possesses several physiological properties that make it (and its analogs) a subject of intensive investigation as a potential treatment of diabetes mellitus, The known physiological functions of GLP-1 include:

increases insulin secretion from the pancreas in a glucose-dependent manner.

decreases glucagon secretion from the pancreas.

increases beta cells mass and insulin gene expression.

inhibits acid secretion and gastric emptying in the stomach.

decreases food intake by increasing satiety.

Commerce clause

Are You Interested in GLP-1 (7-37) Acetate or Other Polypeptide.please feel free to contact us.

White Oral Strongest Anabolic Steroid Cutting Cycle Stanozolol Winstrol CAS 10418-03-8